Last June JAMA Internal Medicine published an excellent systematic review and meta-analysis
of clinical trials of sublingual immunotherapy for grass pollen allergy [
[1]
]. The team of Di Lorenzo of the University of Palermo reached an important result
indicating a small, unimpressive effect of sublingual immunotherapy. These findings
probably justify no longer this kind of intervention to be paid by any European health
care system. Accordingly, the Editor of JAMA has thrown a “caveat emptor” [
[2]
] that is similar to a scream towards public welfare managers.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis.JAMA Intern Med. Aug. 1, 2015; 175: 1301-1309
- Caveat emptor on sublingual immunotherapy.JAMA Intern Med. Aug. 1, 2015; 175: 1310
- Evidence-based knowledge management: an approach to effectively promote good health-care decision-making in the information era.Intern Emerg Med. Apr 2009; 4: 99-106
- Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.J Allergy Clin Immunol. Nov 2012; 130: 1097-1107
Article info
Publication history
Published online: September 13, 2015
Accepted:
August 31,
2015
Received in revised form:
August 28,
2015
Received:
August 11,
2015
Identification
Copyright
© 2015 European Federation of Internal Medicine. Published by Elsevier Inc. All rights reserved.